The introduction of nicotinamide to be a nicotine alternative in e-cigarette and smokeless goods represents a major regulatory obstacle for your FDA. Nicotinamide doesn't have nicotinic receptor agonist action and is understood to act as a sedative at significant dosages6. The claims created by